Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: RNVO
Latest Price: 17.88p  (1.42% Ascending)
52-week High: 17.63p
52-week Low: 13.25p
Market Cap: 28.21M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Renovo Group Plc
www.renovo.com

Renovo (LSE:RNVO) is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. 

Pdf

Renovo Group: Brooke to succeed Ferguson as chairman

9th Jan 2012, 3:50 pm by Giles Gwinnett Professor Ferguson is resigning from his role as non- exec chairman and consultant on the same day

Renovo Group (LON:RNVO) told investors that non-executive director Jamie Brooke will succeed Professor Mark WJ Ferguson as chairman of the company on January 15 this year.

Professor Ferguson is resigning from his role as non- exec chairman and consultant on the same day.

He has been appointed Director General of Science Foundation Ireland (SFI) with effect from January 16, Renovo said in a statement.

The Renovo board will now comprise a non-executive chairman, non-exec director and a finance director, it added.

Based in Dublin, SFI invests in world class research in areas of strategic importance and strength to the Irish economy.

Since its foundation in 2000, it has invested 1.4 billion Euros in research projects and currently funds over 900 active research projects and a community of over 3000 researchers.

Professor Ferguson said he was looking forward to ensuring that research output was appropriately exploited by small, medium and large companies to create jobs and companies which will contribute to economic growth in Ireland.

Also in the statement, Brooke wished Professor Ferguson well for the future and thanked him for his invaluable contribution to Renovo.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.